Drug Profile
Research programme: induced pluripotent stem cell derived therapeutics - Center for iPS Cell Research Application/Takeda
Alternative Names: iPS cell based therapeutics - CiRA/Takeda; NGLY1 deficiency therapeutic - CiRA/Takeda/RIKENLatest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Center for iPS Cell Research and Application; Takeda
- Developer Center for iPS Cell Research and Application; RIKEN; Takeda
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; Stem cell therapies
- Mechanism of Action Cell replacements; Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Diabetes mellitus; Heart failure; Inborn genetic disorders; Neurological disorders
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for research development in Cancer in Japan (Parenteral)
- 28 Jul 2021 No recent reports of development identified for research development in Inborn genetic disorders in Japan (Parenteral)
- 18 Jul 2019 Induced pluripotent stem cell derived therapeutics is still in research phase for Cancer in Japan